Revolution Medicines (formerly Midasyn, inc.) is developing a platform to rapidly open chemical space hereto inaccessible for drug development while enabling PhD chemists to focus on the utility of the molecules rather than the synthesis of the molecules.
Martin D. Burke, Michael Fischbach, and Kevan Shokat co-founded Revolution Medicine in 2014. All three founders have extensive backgrounds in chemistry, bioengineering, and health sciences.
EnterpriseWorks Tenure: 2014-2015
News & Milestones
- Third Rock Ventures Invests $45 Million in Revolution Medicines
- EnterpriseWorks Graduate, Revolution Medicines, receives $56M Series B
- Revolution Medicines, EnterpriseWorks Graduate, Secures $100 Million to Target RAS Pathway
- Revolution Medicines, EnterpriseWorks Graduate, Went Public
- Revolution Medicines Announces U.S Patent
Revolution Medicines Milestones After the Research Park
After graduating from EnterpriseWorks in 2015, Revolution Medicines opened its corporate office in Redwood City, CA.
July 2024, Revolution Medicines announced that its experimental drug, RMC-6236, showed encouraging results in shrinking pancreatic tumors in a quarter of patients in early trials.